Clinical trials
Second Line clinical trials
Below are recruiting second line clinical trials, each written for real people, not researchers. We’re tracking 113 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06532617RecruitingPhase 2
New drug combo for advanced pancreatic cancer after first treatment
This trial tests a new drug combo (cadonilimab plus either S-1 or capecitabine) for people with advanced pancreatic cancer that has not spread to other organs and who have already tried one standard treatment. The goal is to see if this combination can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07091019Recruiting
CML patient experience study on standard TKI therapy
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Birmingham, AlabamaAges 18–100 - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT07073079Recruiting
Study of upadacitinib and risankizumab for Crohn's after first therapy
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
Castellana Grotte, BariAges 18 years+ - NCT07062536RecruitingPhase 2
Comparing Two Chemo Combos for Advanced Bile Duct Cancer
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Busan, BusanAges 19–99 - NCT07047560RecruitingPhase 2
A new chemo combo for advanced colorectal cancer
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07046611RecruitingPhase 2/Phase 3
Ketamine and Levetiracetam for Seizures in Children
This study tests whether two medicines, ketamine (a sleep medicine) and levetiracetam (a seizure medicine), work better than a standard treatment for stopping long-lasting seizures in children when the first rescue medicine doesn't work.
SohagAges 1–16 - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT06929936RecruitingPhase 2
Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Xiamen, FujianAges 18 years+ - NCT06904378RecruitingPhase 1/Phase 2
New drug combo for advanced pancreatic cancer
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
St Louis, MissouriAges 18 years+ - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT06838910RecruitingPhase 2
Tislelizumab and anlotinib for thymus cancer after first treatment
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06788756RecruitingPhase 2/Phase 3
Testing L-Annamycin plus Cytarabine for relapsed AML
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Birmingham, AlabamaAges 18–80 - NCT06418789RecruitingPhase 2
High-dose chemo for relapsed germ cell tumors
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
Saint Petersburg, Russian FederationAges 18 years+ - NCT06686771RecruitingPhase 3
Radiation for limited growth in advanced lung cancer on immunotherapy
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
Phoenix, ArizonaAges 18 years+ - NCT06676527Recruiting
Vorolanib for advanced kidney cancer after first treatment
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
Nanjing, JiangsuAges 18–80 - NCT06662006RecruitingPhase 2
Nal-IRI chemo with immunotherapy and radiation for pancreatic cancer
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Nanjing, JiangsuAges 18–75 - NCT06258642Recruiting
Irinotecan liposome plus anlotinib for SCLC after first chemo
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
Tucson, ArizonaAges 18 years+ - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT06213311RecruitingPhase 2
CAR T-cells plus antibody drug for relapsed large B-cell lymphoma
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Houston, TexasAges 18 years+
Hear when a new Second Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for second line?
- Yes. Clin2 currently lists 113 recruiting second line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a second line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a second line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.